Pharming's Joenja Nears EU Approval for Rare Immunodeficiency
Event summary
- Pharming's Joenja (leniolisib) received a positive CHMP opinion for treating APDS in patients 12+ years old.
- Final EU approval expected in Q2 2026 under exceptional circumstances.
- Approval based on Phase II/III trial showing statistically significant immune dysregulation improvements.
- Joenja is already approved in the US, UK, Australia, Israel, and Japan.
The big picture
Pharming's potential EU approval for Joenja marks a significant step in addressing the unmet medical need for APDS, a rare primary immunodeficiency with a global prevalence of 1-2 per million. The positive CHMP opinion follows recent approvals in Japan and underscores the growing recognition of targeted therapies in rare disease treatment. The strategic focus on APDS positions Pharming as a key player in the niche but expanding rare disease market.
What we're watching
- Regulatory Momentum
- Whether the positive CHMP opinion will translate into swift European Commission approval and patient access.
- Commercial Expansion
- How Pharming will position Joenja in Europe against its existing approvals in other regions.
- Pipeline Potential
- The progress of leniolisib's regulatory reviews in Canada and other countries, as well as its Phase II trials in other primary immunodeficiencies.
Related topics